1. Introduction {#s0005}
===============

Worldwide, about 17 million people die from cardiovascular disease (CVD) each year, chiefly from ischemic heart disease (IHD) and stroke, with about three-quarters of these deaths now occurring in low- or middle-income countries, including China [@bb0005; @bb0015; @bb0020]. In most Western countries, the mortality rates from CVD have declined progressively in the last few decades, due partly to widespread and long-term use of proven medication, such as antiplatelet therapy, statins, β-blockers and ACE-inhibitors (ACE-I), for the secondary prevention of CVD events, and partly due to favourable changes in underlying risk factors, such as smoking and dietary patterns [@bb0025; @bb0035; @bb0040; @bb0045; @bb0050; @bb0055]. Although the acute hospital management of patients with CVD in China is generally similar to that in most Western countries [@bb0060], relatively little is known about the use of drug treatment for secondary prevention of CVD events in the community in China. We examined cross-sectional data about the use of medication for secondary prevention of CVD (which is defined as IHD and or stroke throughout this paper) among adults who were recruited in the China Kadoorie Biobank (CKB) Study from over 1737 rural and urban communities in China [@bb0065; @bb0070]. The aims of the present study were to examine the use of six specific classes of drug treatment for secondary prevention of CVD and relevance to it of a range of demographic, socioeconomic, lifestyle and health-related factors.

2. Methods {#s0010}
==========

2.1. Study participants {#s0025}
-----------------------

The present study population consisted of 23 129 participants in the CKB who reported having a history of doctor-diagnosed IHD and/or stroke (including transient ischemic attack \[TIA\]) at the baseline survey. Details of the design, survey methods and baseline characteristics of the CKB participants have been reported previously [@bb0065; @bb0070]. In brief, the CKB study involved 512 891 people who were recruited during 2004--8 from 1737 communities in 10 geographically diverse regions (5 urban and 5 rural) of China, chosen according to local disease patterns, exposure to certain risk factors, population stability, quality of death and disease registries, local commitment and capacity. In each region, all men and women aged 35--74 years were identified through official residential records and invited to attend study clinics set up specifically in local residential community centres (with a small number slightly outside of this age range when recruited).

2.2. Data collection {#s0030}
--------------------

The baseline survey included a face-to-face interview by trained study staff with a laptop-administrated questionnaire, physical examination (e.g., height, weight, blood pressure, heart rate and lung function) and collection of blood for storage and future analysis. At the interview, apart from a range of questions related to demographic and lifestyle factors (e.g., smoking, alcohol, diet and physical activity) a detailed medical history was sought from participants, with the question: "*Has a doctor EVER told you that you had the following disease?*" followed by a list of about 20 major conditions, including IHD and stroke. If a study participant had a prior history of IHD and/or stroke, they were then asked about the age of first diagnosis and whether they were currently taking any drug treatment, and if so, whether this included any of six specific classes of drug (anti-platelet, statins, diuretics, ACE-I, β-blockers and calcium-channel blockers) that are used for the secondary prevention of CVD events. To facilitate the recording of drugs that were used a detailed list of possible drug names (including generic and commercial names) for each of these six classes of drug was provided to participants. All participants provided written informed consent to take part in the CKB study. Ethics approvals were obtained from Central Ethical Committee of the Chinese Centre for Disease Control and Prevention (CDC), Beijing, China, and the University of Oxford UK, as well as from the Institutional Research Boards in the 10 study regions.

2.3. Statistical analysis {#s0035}
-------------------------

The proportions of participants with prior CVD who were using the six classes of drug were calculated separately for participants who had either IHD or stroke, or both, and were adjusted for age, gender, geographical region and education. Multivariate logistic regression models were used to estimate rates of use of these drugs, calculate odds ratios (OR) and 95% confidence intervals (CIs) among participants with prior CVD both overall and for IHD or stroke, in different categories of baseline variables (including CVD risk factors). Odds ratio (and 95% CI) of use of six proven CVD medications by levels of systolic blood pressure (SBP) were estimated for each group relative to the lowest and are shown as "floating absolute risks" (which does not alter their values but merely ascribes a 95% confidence interval \[CI\] to the RR in every group) [@bb0075]. All analyses were conducted using SAS version 9.2 (SAS institute Inc., Cary, North Carolina, USA).

3. Results {#s0015}
==========

3.1. Characteristics of the study population {#s0040}
--------------------------------------------

Overall, 23 129 (4.5%) of the CKB participants reported a prior history of CVD, including 15 472 (3.0%) with IHD and 8884 (1.7%) with stroke ([Table 1](#t0005){ref-type="table"}). The prevalence of IHD was higher in women (3.4%) than in men (2.5%) and, consistently, also in those with higher levels of education or of household income ([Table 1](#t0005){ref-type="table"}). For stroke, the prevalence was higher in men (2.2%) than women (1.4%) and, in contrast to IHD, in those with lower levels of education and income. The prevalence of IHD and stroke were both strongly and positively associated with increasing levels of systolic blood pressure and body mass index (BMI) ([Table 1](#t0005){ref-type="table"}). Participants who had poor self-rated health status had a higher prevalence of either IHD or stroke (14.1%) compared with those who had good self-rated health status (2.0%).

3.2. Use of proven drug therapy in participants with prior CVD {#s0045}
--------------------------------------------------------------

Among participants with a prior history of CVD (IHD and/or stroke), the median interval since diagnosis was 5.0 (IQR 2.0--10.0) years and about half of them (55.5%) reported current use of any drug treatment, but only about one-third (35.3%) reported current use of any of the six proven categories of drug treatment for CVD event prevention ([Table 2](#t0010){ref-type="table"}). Among these six drug categories, the reported current use were 1.4% for statins, 2.3% for diuretics, 7.6% for ACE-I, 10.1% for β-blockers, 10.6% for anti-platelet (chiefly aspirin) and 18.2% for calcium channel blockers. Only 9% of these high-risk patients reported concurrent use of two of these drug categories and 2.7% reported concurrent use of three or more. There was little difference in the proportions having individual or combined use of such treatments between those with IHD and stroke.

3.3. Correlate of use of secondary prevention treatments for CVD {#s0050}
----------------------------------------------------------------

[Table 3](#t0015){ref-type="table"} shows the OR (and 95% CI) for use of any of the six proven drug treatment categories by demographic factors (age, gender and region) and socioeconomic status (education level, annual household income) among people with prior CVD adjusted for age, gender, region and education except that when the variable is in question. For IHD, all else being equal, there was lower usage among younger people (e.g., OR 0.44; 95% CI: 0.39--0.50 for \< 50 years versus 70 + years), in women (0.87; 0.80--0.93), and in those living in urban areas (0.78; 0.72--0.85). Less education was associated strongly with less use of any of the six established drug treatments, and of each specific drug category, for both IHD ([Fig. 1](#f0005){ref-type="fig"}, left) and stroke ([Fig. 1](#f0005){ref-type="fig"}, right). By contrast, annual household income was positively associated with use of any of the six drug treatments ([Table 3](#t0015){ref-type="table"}).

[Table 4](#t0020){ref-type="table"} shows the adjusted ORs for use of any of the six classes of drug by alcohol, smoking, SBP, hypertension, BMI, and diabetes mellitus (DM). Usage rates were moderately lower in current smokers (0.84; 0.79--0.89) and current drinkers (0.76; 0.73--0.79), but strongly positively associated with measured BMI and SBP (p for trend \< 0.0001). For every 10 mm Hg higher baseline SBP, the use of these treatments was 16.5% higher (p \< 0.0001; [Fig. 2](#f0010){ref-type="fig"}). Moreover, individuals with self-reported hypertension were almost 8 fold (7.55; 7.08--8.06) as likely to report use of such therapy as those without such a diagnosis, not only for agents with BP-lowering effects (40.7% vs 12.0%) but also for statins (2.1% vs 0.8%) and aspirin (15.4% vs 5.9%) ([Fig. 3](#f0015){ref-type="fig"}, left). The pattern was similar for participants with a history of stroke ([Fig. 3](#f0015){ref-type="fig"}, right). This would leave 56% of IHD patients and 41% of stroke patients in the present study that had not been diagnosed previously with hypertension under-treated despite a high risk of recurrence of IHD or stroke. Higher use of these six drugs also was associated with prior history of DM (1.40; 1.48--1.52) and the pattern was similar for participants with a history of stroke and/or IHD. Years of diagnosis has no significant effect in the use of the six drugs among participants with a history of either IHD or stroke ([Table 4](#t0020){ref-type="table"}). Health status self-rated as good was strongly associated with lower use of the six drugs in individuals with prior IHD (0.52; 0.48--0.57) or stroke (0.58; 0.52--0.65).

4. Discussion {#s0020}
=============

This is the largest community-based study carried out in China on the use of drug therapy for secondary prevention in people with prior IHD and stroke. It shows that only about one-third of patients with CVD in the community were taking any proven medication for secondary prevention of CVD events. The use of 6 proven drug treatments for secondary prevention of CVD was unrelated to the years since diagnosis, but associated with a number of socio-economic (especially low education), lifestyle (e.g., smoking, alcohol drinking) and physiological factors (e.g., BMI and blood pressure). The effect of blood pressure on the use of treatment was particularly striking, and those reporting having a doctor-diagnosed hypertension were almost 8 times as likely to report use of such treatment as those without such a diagnosis.

Although the reported use of various treatments for secondary prevention of IHD and stroke in the present study was generally lower than that reported in clinical settings from particular Chinese cities [@bb0080; @bb0085], our study findings are broadly consistent with the results of the PURE study [@bb0005] among 46 285 participants, aged 35--70 years recruited during 2004--9 from 115 urban and rural communities across China (in addition to participants from 16 other countries). In that study, 3070 (6.6%) of the Chinese participants reported having a history of IHD (5.2%) or stroke (1.9%) and, among them, 18.6%, 6.2%, 8.6%, 14.3%, 14.9% and 1.7%, reported taking antiplatelet drug, β-blockers, ACE-I, diuretics, calcium-channel blockers and statins [@bb0005] compared with 10.6%, 10.1%, 7.6%, 2.3%,18.2% and 1.4% respectively in the present study. In both the PURE-China study and CKB, the use of anti-platelet agents (18.6% and 10.6%) and any of the BP-lowering drugs (38.2% and 34.4%) for participants with a history of either IHD or stroke in China was much lower than participants in the PURE study from North America (antiplatelet drugs: 52.2%, BP-lowering medication: 69.2%), Middle East (49.7%, 64.3%) and South Americans (29.0%, 57.8%) and only slightly better than among participants from South Asia (9.3%, 18.8%), Malaysia (13.6%, 23.9%) and Africa (5.7%, 15.9%). In addition, there was also virtually no long-term use of statins among patients with IHD and/or stroke in the communities of China (IHD: 2% in PURE-China and 1.4% in CKB; stroke: 0.8% in both studies) during 2004--2008. These figures were similar to these for PURE in Africa (1.4% for IHD; 0% for stroke), but much lower than those observed in North America and Europe (56.7%; 38.7%).

Several factors could affect the use of drug therapy for secondary prevention of CVD events after discharge from hospital, including local treatment guidelines, doctors\' knowledge and beliefs, concerns about adverse effects, uncertainty about diagnosis and disease severity, affordability, patients\' awareness of the risks and self-perceived health status. Firstly, the six proven drugs for secondary prevention of CVD events selected in the present study are all recommended by Chinese guidelines, not only for IHD [@bb0090] but also for ischemic stroke and TIA [@bb0095]. Indeed, a recent nationwide survey in China found that over 95% of doctors across over 1029 different types of hospitals said that they would prescribe a statin at discharge for long-term secondary prevention of IHD or stroke [@bb0060]. So, it seems unlikely that the knowledge or beliefs of hospital doctors in China would influence its long-term use, even though there is recent evidence that use of higher doses of statins (e.g., simvastatin \> 40 mg) would lead to much greater risk of myopathy in Chinese [@bb0100] than in Western populations [@bb0105]. On the other hand, the uncertainty of diagnosis and disease severity may contribute to the relatively lower use in urban than in rural areas in the present study, which is opposite to that seen in the PURE-China study [@bb0005].

As in PURE [@bb0005], we also found the use of the drug treatment was associated with socioeconomic status, smoking and alcohol drinking. The significantly lower use of medication among regular smokers or drinkers may reflect the so-called "crowding out effect" [@bb0110] where the costs of smoking and drinking compromised the allocation of expenditure for essential treatment. Although most of the CKB participants had certain health insurance cover at baseline, no specific information was available at baseline about type of health insurance cover and level of reimbursement. In China, health insurance coverage has risen rapidly during the last 10 year, from 29.7% in 2003 to \> 90% in 2010 [@bb0115], but in most rural areas the average reimbursement rate for outpatient care under the New Rural Cooperative Health Scheme (NCMS) is only about 10% [@bb0120]. As secondary treatments were mostly prescribed in the outpatient clinic, their use is more likely to be affected by the price of the drugs and the reimbursement policy. Of the six proven drug treatment categories, statins were the most expensive, costing for example 2555 RMB (\~£270) a year for daily treatment with 20 mg simvastatin between 2004 and 2008 [@bb0125], with little difference in price between generic and non-generic drugs, which may account for its extremely low use in the present study population during that period.

Self-rated health status has been recognised as a useful index for use of health services [@bb0130; @bb0135] and a predictor for future vascular events and mortality [@bb0135]. The present study is, to our knowledge, the first to report the association between self-rated health status and usage of long-term medication. Those who self-rated their health status as "poor" were nearly twice as likely to be on secondary prevention treatments compared with those with "good" health status, suggesting that feeling good about their health is an important determinant of non-medication or non-adherence to medication in individuals. It is not clear in the present study population whether the self-reported health status is correlated with the severity of the disease diagnosed.

The most important finding in the present study is, perhaps, that the treatment rate in secondary prevention is influenced strongly by the awareness of the individual risk factors rather than overall absolute risk. Many CVD patients even in the "so-called" normal range of distribution of blood pressure and cholesterol are at substantial absolute risk of developing further cardiovascular events. There is well-established randomised evidence that blood pressure [@bb0140] and lipid lowering treatments confer substantial benefit regardless of pre-treatment levels of blood pressure or blood cholesterol [@bb0145]. On the other hand, some drug classes that are widely used for blood pressure lowering treatment (such as β-blocker and ACE-I) have also been shown to be particularly effective for secondary prevention following IHD [@bb0040; @bb0045]. It is not clear whether the treatment pattern observed in this study reflects a lack of understanding by Chinese doctors about the effects of these treatments, or is driven mainly by reimbursement policies, or both.

One of the limitations of the present study is that it was not designed to be nationally representative, so the findings should be generalized with caution to the overall Chinese population. Moreover, the diagnosis of CVD and use of six proven drug categories were based on self-reported data without any objective validation. However, both the prevalent rates of self- reported IHD and stroke, as well as the treatment patterns, in the present study were comparable to those reported by the PURE-China study, in which 89% of the participants with self-reported IHD and/or stroke had their diagnoses confirmed by central adjudication [@bb0005]. There is also good evidence from many other studies in different populations that self-reported IHD and stroke have a high degree of specificity [@bb0155; @bb0160; @bb0165; @bb0170; @bb0175].

In summary this large community-based survey of 1737 rural and urban communities of China found that only 1 in 3 individuals with a history of CVD receive any established secondary preventive treatments. While lack of appropriate awareness of perceived risk among patients may contribute to substantial under-use of such therapy, several other factors could also play an important role, including inappropriate reimbursement policies (e.g., short period of reimbursement for statins following CVD) which should be addressed.
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![Percentage use of six proven CVD medication categories by level of education in participants with a history of IHD (left) or stroke (right). Vertical lines indicate 95% CIs.](gr1){#f0005}

![Odds ratio of use of six proven CVD medication categories by levels of systolic blood pressure in participants with a history of cardiovascular disease. Numbers of people with prior CVD are also given for each group. Odds ratios are plotted on a floating absolute scale. Each closed square has an area inversely proportional to the effective variance of the log of the odds ratio. Vertical lines indicate 95% CIs.](gr2){#f0010}

![Percentage use of six proven CVD medication categories in participants with and without doctor-diagnosed hypertension among those with IHD (left) and stroke (right). Vertical lines indicate 95% CIs.](gr3){#f0015}

###### 

Selected baseline characteristics of study participants, by history of IHD, stroke and either or both.

                                   All (n = 512 891)   History of IHD (n = 15 472)   History of stroke (n = 8884)   History of either or both (n = 23 129)                            
  -------------------------------- ------------------- ----------------------------- ------------------------------ ---------------------------------------- ------- ---------------- --------
  Age (years)                                                                                                                                                                         
   \< 50                           230 553             1510                          (0.6)                          798                                      (0.4)   2277             (1.0)
   50--59                          157 556             4502                          (3.0)                          2690                                     (1.8)   6938             (4.6)
   60--69                          91 771              6416                          (7.0)                          3664                                     (4.0)   9481             (10.4)
   70--79                          33 011              3044                          (8.6)                          1732                                     (4.6)   4433             (12.5)
   *Mean (SD)*                                         *61.4 (8.7)*                                                 *61.5 (8.4)*                                     *61.2 (8.6)*     
  Gender                                                                                                                                                                              
   Male                            210 222             5714                          (2.5)                          4912                                     (2.2)   10 069           (4.5)
   Female                          302 669             9758                          (3.4)                          3972                                     (1.4)   13 060           (4.5)
  Region                                                                                                                                                                              
   Rural                           286 705             4963                          (2.8)                          3615                                     (1.2)   8347             (3.8)
   Urban                           226 186             10 509                        (3.3)                          5269                                     (2.4)   14 782           (5.3)
   Education                                                                                                                                                                          
   No formal school                95 221              2399                          (2.3)                          1518                                     (1.7)   3758             (3.7)
   Primary school                  165 216             4958                          (2.9)                          3053                                     (1.8)   7689             (4.5)
   Middle school                   144 913             3804                          (3.2)                          2322                                     (1.8)   5783             (4.7)
   High school                     77 527              2645                          (3.7)                          1292                                     (1.6)   3712             (5.0)
   College/university              30 014              1666                          (3.9)                          699                                      (1.3)   2187             (4.9)
  Household income (Yuan/year)                                                                                                                                                        
   \< 4999                         50 203              1232                          (2.6)                          1133                                     (2.0)   2272             (4.4)
   5000--9999                      94 629              2263                          (2.8)                          1505                                     (1.9)   3630             (4.5)
   10 000--19 999                  149 013             5099                          (3.0)                          2937                                     (1.8)   7625             (4.5)
   20 000--34 999                  126 721             4101                          (3.1)                          2026                                     (1.6)   5781             (4.5)
   35 000 +                        92 325              2777                          (3.4)                          1283                                     (1.5)   3821             (4.7)
  Cigarette smoking                                                                                                                                                                   
   Never                           317 614             10 079                        (3.1)                          4458                                     (1.7)   13 845           (4.5)
   Ex                              30 563              1901                          (4.4)                          1612                                     (2.9)   3274             (7.1)
   Current                         164 714             3492                          (2.7)                          2814                                     (1.6)   6010             (4.0)
  Alcohol drinking                                                                                                                                                                    
   Never                           235 199             7853                          (3.4)                          4024                                     (2.2)   11 270           (5.4)
   Ex                              9256                647                           (6.6)                          754                                      (6.3)   1317             (13.1)
   Current                         268 436             6972                          (2.5)                          4106                                     (1.2)   10 542           (3.5)
  SBP (mm Hg)                                                                                                                                                                         
   \< 120                          163 260             3046                          (2.5)                          1065                                     (0.9)   3950             (3.2)
   120--139                        201 619             5578                          (3.1)                          2851                                     (1.6)   8050             (4.5)
   140--159                        96 713              4185                          (3.5)                          2731                                     (2.4)   6517             (5.6)
   160 +                           51 299              2663                          (3.7)                          2237                                     (3.5)   4612             (6.8)
   *Mean (SD)*                                         *140.0 (22.6)*                                               *145.5 (23.6)*                                   *141.2 (23.1)*   
  BMI (kg/m2)                                                                                                                                                                         
   \< 22.0                         168 547             3000                          (2.0)                          1901                                     (1.2)   4720             (3.1)
   22.0--24.9                      175 414             4660                          (2.9)                          2953                                     (1.8)   7240             (4.4)
   25.0--26.9                      85 856              3255                          (3.6)                          1853                                     (2.1)   4846             (5.4)
   27 +                            83 074              4557                          (4.6)                          2177                                     (2.4)   6323             (6.7)
   *Mean (SD)*                                         *25.1 (3.7)*                                                 *24.7 (3.4)*                                     *24.9 (3.6)*     
  Self-reported hypertension       59 703              6749                          (8.6)                          5212                                     (7.6)   11 141           (15.7)
  Self-reported diabetes           16 162              2053                          (6.9)                          1107                                     (4.0)   2849             (10.3)
  Self-rated poor health status    53 105              4297                          (8.4)                          3300                                     (6.2)   7028             (14.1)
  Short of breath during walking   30 351              3341                          (10.8)                         1274                                     (3.9)   4305             (14.1)

Adjusted for age, gender, region and education except when the variable is in question.

###### 

Use of any secondary prevention drug treatment among participants with a prior history of IHD, stroke and either or both at baseline.

  ------------------------------------------------------------------------------------------------------------------------------------
                              IHD (n = 15 472)   Stroke (n = 8884)   Either or both (n = 23 129)                              
  --------------------------- ------------------ ------------------- ----------------------------- -------- ----------------- --------
  Any treatment               8739               (56.4)              4598                          (51.8)   12 841            (55.5)

  Any of six drugs            5382               (34.8)              3396                          (38.2)   8156              (35.3)

   Calcium channel blockers   2722               (17.6)              1824                          (20.5)   4211              (18.2)

   β-Blockers                 1903               (12.3)              634                           (7.1)    2341              (10.1)

   ACE-I                      1045               (6.8)               857                           (9.6)    1761              (7.6)

   Diuretics                  351                (2.3)               246                           (2.8)    536               (2.3)

   Anti-platelet              1557               (10.1)              1098                          (12.4)   2447              (10.6)

   Statins                    215                (1.4)               137                           (1.5)    319               (1.4)

  Year since diagnosis\       6.5 (2.5--11.5)                        4.5 (1.5--8.5)                         5.0 (2.0--10.0)   
  Median (IQR)                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------

###### 

Use of any secondary prevention drug treatment among participants with a prior history of IHD, stroke and either or both at baseline by demographic and socioeconomic characteristics.

  Baseline measure               IHD (n = 15 472)   Stroke (n = 8 884)   Either or both (n = 23 129)                                                     
  ------------------------------ ------------------ -------------------- ----------------------------- ------- ------ ------------------- ------- ------ -------------------
  Age group (years)                                                                                                                                      
   \< 50                         362                22.6                 0.44 (0.39--0.50)             306     34.6   0.81 (0.69--0.94)   652     26.3   0.56 (0.51--0.62)
   50--59                        1471               31.7                 0.71 (0.66--0.75)             1 057   37.7   0.92 (0.85--1.00)   2 397   33.3   0.78 (0.75--0.82)
   60--69                        2395               37.5                 0.91 (0.87--0.96)             1 407   38.7   0.96 (0.90--1.03)   3 496   37.1   0.93 (0.89--0.97)
   70 +                          1154               39.6                 1.00 (0.92--1.09)             626     39.7   1.00 (0.90--1.11)   1 611   38.9   1.00 (0.93--1.07)
   *P (Trend)*                                                           \< *0.0001*                                  *0.14*                             \< *0.0001*
  Gender                                                                                                                                                 
   Male                          2207               36.8                 1.00                          1 913   37.4   1.00                3 823   36.3   1.00
   Female                        3175               33.6                 0.87 (0.80--0.93)             1 483   39.2   1.08 (0.98--1.19)   4 333   34.4   0.92 (0.87--0.98)
   *P (Heterogeneity)*                                                   \< *0.0001*                                  *0.11*                             \< *0.01*
  Region                                                                                                                                                 
   Rural                         1807               38.6                 1.00                          1 607   46.8   1.00                3 264   41.3   1.00
   Urban                         3575               33.0                 0.78 (0.72--0.85)             1 789   32.4   0.54 (0.49--0.60)   4 892   31.9   0.67 (0.62--0.71)
   *P (Heterogeneity)*                                                   \< *0.0001*                                  \< *0.0001*                        \< *0.0001*
  Education level                                                                                                                                        
   No formal                     684                26.6                 1.00 (0.90--1.11)             471     27.3   1.00 (0.87--1.15)   1 080   26.0   1.00 (0.92--1.09)
   Primary                       1830               33.7                 1.40 (1.32--1.50)             1 242   36.1   1.51 (1.39--1.63)   2 887   33.8   1.45 (1.38--1.53)
   Middle                        1335               37.1                 1.63 (1.52--1.74)             895     41.2   1.87 (1.71--2.04)   2 069   38.0   1.74 (1.65--1.84)
   High                          974                39.7                 1.82 (1.68--1.98)             527     46.1   2.28 (2.02--2.56)   1 389   41.2   1.99 (1.86--2.14)
   College/university            559                36.6                 1.59 (1.43--1.78)             261     46.7   2.33 (1.98--2.75)   731     38.8   1.80 (1.64--1.99)
   *P (Heterogeneity)*                                                   \< *0.0001*                                  \< *0.0001*                        \< *0.0001*
  Household income (Yuan/year)                                                                                                                           
   \< 4999                       361                27.7                 1.00 (0.87--1.14)             415     34.5   1.00 (0.87--1.15)   735     30.2   1.00 (0.91--1.10)
   5000--9999                    744                32.6                 1.26 (1.15--1.38)             601     38.0   1.16 (1.04--1.30)   1 276   34.3   1.21 (1.12--1.30)
   10 000--19 999                1826               35.7                 1.45 (1.36--1.53)             1 091   37.5   1.14 (1.05--1.23)   2 700   35.4   1.27 (1.21--1.33)
   20 000--34 999                1457               35.5                 1.44 (1.34--1.54)             793     40.2   1.28 (1.16--1.41)   2 071   36.2   1.31 (1.24--1.39)
   35 000 +                      994                36.9                 1.53 (1.39--1.67)             496     40.5   1.29 (1.13--1.47)   1 374   37.4   1.38 (1.28--1.49)
   *P (Trend)*                                                           \< *0.0001*                                  *0.05*                             \< *0.0001*

Adjusted for age, gender, region and education except when the variable is in question.

###### 

Odds ratios for use of any secondary prevention drug treatment by lifestyle and physical measurements.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
                               IHD\            Stroke (n = 8 884)   Either or both (n = 23 129)                                                   
                               (n = 15 472)\                                                                                                      
                               (n = 5 382)                                                                                                        
  ---------------------------- --------------- -------------------- ----------------------------- ------ ------ ------------------- ------ ------ -------------------
  Cigarette smoking                                                                                                                               

   Never                       3431            35.8                 1.00 (0.92--1.09)             1711   38.6   1.00 (0.89--1.12)   4785   36.0   1.00 (0.93--1.08)

   Ex                          761             36.9                 1.05 (0.95--1.15)             662    42.5   1.17 (1.06--1.30)   1299   38.3   1.11 (1.03--1.19)

   Current                     1190            30.8                 0.80 (0.74--0.86)             1023   35.1   0.86 (0.79--0.93)   2072   32.0   0.84 (0.79--0.89)

   *P (Trend)*                                                      \< *0.0001*                                 \< *0.0001*                       \< *0.0001*

  Alcohol drinking                                                                                                                                

   Never                       2899            40.6                 1.00 (0.94--1.06)             1632   39.9   1.00 (0.92--1.08)   4215   37.8   1.00 (0.95--1.05)

   Ex                          287             30.9                 1.13 (0.96--1.33)             351    46.6   1.32 (1.13--1.54)   590    42.9   1.23 (1.10--1.38)

   Current                     2 196           34.8                 0.74 (0.70--0.78)             1413   35.1   0.81 (0.76--0.87)   3351   31.6   0.76 (0.73--0.79)

   *P (Heterogeneity)*                                              \< *0.0001*                                 \< *0.0001*                       \< *0.0001*

  SBP (mm Hg)                                                                                                                                     

   \< 120                      695             23.3                 1.00 (0.92--1.09)             254    23.6   1.00 (0.86--1.16)   888    22.6   1.00 (0.93--1.08)

   120--139                    1760            31.3                 1.50 (1.42--1.59)             972    33.9   1.66 (1.54--1.80)   2560   31.5   1.57 (1.50--1.65)

   140--159                    1663            39.5                 2.16 (2.03--2.30)             1116   41.4   2.29 (2.12--2.48)   2562   39.5   2.23 (2.12--2.35)

   160 +                       1264            47.9                 3.04 (2.80--3.29)             1054   46.9   2.87 (2.62--3.13)   2146   46.8   3.02 (2.84--3.20)

   *P (Trend)*                                                      \< *0.0001*                                 \< *0.0001*                       \< *0.0001*

  BMI (kg/m2)                                                                                                                                     

   \< 22.0                     785             23.2                 1.00 (0.92--1.09)             594    27.2   1.00 (0.90--1.11)   1308   24.5   1.00 (0.93--1.07)

   22.0--24.9                  1626            33.8                 1.69 (1.59--1.80)             1097   36.1   1.52 (1.40--1.64)   2541   34.0   1.59 (1.52--1.67)

   25.0--26.9                  1173            36.4                 1.89 (1.76--2.04)             737    41.1   1.87 (1.70--2.06)   1777   37.3   1.84 (1.73--1.95)

   27.0 +                      1798            42.3                 2.42 (2.27--2.59)             968    48.3   2.50 (2.28--2.74)   2530   43.2   2.35 (2.23--2.49)

   *P (Trend)*                                                      \< *0.0001*                                 \< *0.0001*                       \< *0.0001*

  Years since diagnose                                                                                                                            

   \< 3                        1418            35.0                 1.00 (0.94--1.07)             1288   38.6   1.00 (0.93--1.08)   2449   35.3   1.00 (0.95--1.05)

   3 to \< 7                   1518            34.3                 0.97 (0.91--1.03)             1147   38.9   1.01 (0.94--1.09)   2448   35.0   0.99 (0.94--1.04)

   7 +                         2446            35.0                 1.00 (0.95--1.06)             961    37     0.93 (0.86--1.01)   3259   35.4   1.01 (0.96--1.06)

   *P-Trend*                                                        *0.69*                                      *0.29*                            *0.88*

  Self-reported diabetes                                                                                                                          

   No                          4512            33.6                 1.00                          2914   37.2   1.00                6979   34.3   1.00

   Yes                         870             42.4                 1.45 (1.32--1.60)             482    45.4   1.41 (1.23--1.61)   1177   42.2   1.40 (1.28--1.52)

   *P (Heterogeneity)*                                              \< *0.0001*                                 \< *0.0001*                       \< *0.0001*

  Self-reported hypertension                                                                                                                      

   No                          1428            15.9                 1.00                          525    13.7   1.00                1861   15.0   1.00

   Yes                         3954            59.2                 7.69 (7.10--8.31)             2871   55.5   7.88 (7.04--8.82)   6295   57.1   7.55 (7.08--8.06)

   *P (Heterogeneity)*                                              \< *0.0001*                                 \< *0.0001*                       \< *0.0001*

  Self-rated health status                                                                                                                        

   Poor                        1777            42.2                 1.00 (0.94--1.07)             1428   43.1   1.00 (0.93--1.07)   2883   41.3   1.00 (0.95--1.05)

   Fair                        2744            33.7                 0.70 (0.67--0.73)             1498   37.2   0.78 (0.73--0.84)   3992   34.4   0.74 (0.12--0.78)

   Good                        861             27.5                 0.52 (0.48--0.57)             470    30.7   0.58 (0.52--0.65)   1281   28.3   0.56 (0.52--0.56)

   *P (Heterogeneity)*                                              \< *0.0001*                                 \< *0.0001*                       \< *0.0001*
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

Adjusted for age, gender, region and education.
